| First Author | Esche C | Year | 1998 |
| Journal | Cancer Res | Volume | 58 |
| Issue | 3 | Pages | 380-3 |
| PubMed ID | 9458075 | Mgi Jnum | J:46059 |
| Mgi Id | MGI:1197042 | Citation | Esche C, et al. (1998) FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma. Cancer Res 58(3):380-3 |
| abstractText | Successful treatment of melanoma and lymphoma may result from the induction of specific antitumor immunity. Dendritic cells (DCs) are powerful antigen-presenting cells and show a remarkable capacity to stimulate antigen-specific T-cell responses. Administration of FLT3 ligand (FL) results in a reversible accumulation of functionally active DCs in both lymphoid and nonlymphoid tissues. Therefore, we evaluated the possible antitumor effect of FL in murine melanoma (B16 and CL8-1) and lymphoma (EL-4) models. In all experiments, tumor growth was significantly inhibited by FL administration. Analysis by immunohistochemistry revealed an increase in the DC accumulation within B16 and EL-4 tumors after treatment with FL. No change was observed for CL8-1 melanoma. These data suggest a potential role for FL in the immunotherapy of malignant skin tumors and possible DC involvement in this effect. |
